Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4 Breast Neoplasms 3 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Risk Reduction Behavior 1 Patient Preference 1 Patient Acceptance of Health Care 1 Health Behavior 1 Esophageal Neoplasms 1 Diabetes Mellitus 1 Coronary Disease 1 Behavior 1 Barrett Esophagus 1 Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 295 Capecitabine 209 Fluorouracil 183 Cisplatin 172 Docetaxel 140 S 1 (combination) 135 Paclitaxel 128 Leucovorin 117 Irinotecan 110 pembrolizumab 104 Trastuzumab 76 Nivolumab 59 apatinib 57 Drug Therapy 52 sintilimab 46 Surgical Procedures, Operative 45 Ramucirumab 40 Radiotherapy 40 Bevacizumab 37 Hyperthermic Intraperitoneal Chemotherapy 34 Epirubicin 32 titanium silicide 31 tislelizumab 31 Carboplatin 31 Gastrectomy 28 Cyclophosphamide 27 XELOX 25 Tegafur 24 Folfox protocol 23 Albumin-Bound Paclitaxel 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Stomach Neoplasms × Risk Assessment × Clear all

NCT06306755 2025-01-24

ERSS-EGC

Peking University Cancer Hospital & Institute

Phase NA Recruiting

21,000 enrolled

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡